{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T05:58:34Z","timestamp":1776923914827,"version":"3.51.2"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:00:00Z","timestamp":1670371200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:00:00Z","timestamp":1670371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>We conducted a systematic review examining the cost effectiveness of a 3-month course of isoniazid and rifapentine, known as 3HP, given by directly observed treatment, compared to 9\u2009months of isoniazid that is directly observed or self-administered, for latent tuberculosis infection. 3HP has shown to be effective in reducing progression to active tuberculosis and like other short-course regimens, has higher treatment completion rates compared to standard regimens such as 9\u2009months of isoniazid. Decision makers would benefit from knowing if the higher up-front costs of rifapentine and of the human resources needed for directly observed treatment are worth the investment for improved outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We searched PubMed, Embase, CINAHL, LILACS, and Web of Science up to February 2022 with search concepts combining latent tuberculosis infection, directly observed treatment, and cost or cost-effectiveness. Studies included were in English or French, on human subjects, with latent tuberculosis infection, provided information on specified anti-tubercular therapy regimens, had a directly observed treatment arm, and described outcomes with some cost or economic data. We excluded posters and abstracts, treatment for multiple drug resistant tuberculosis, and combined testing and treatment strategies. We then restricted our findings to studies examining directly-observed 3HP for comparison. The primary outcome was the cost and cost-effectiveness of directly-observed 3HP.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We identified 3 costing studies and 7 cost-effectiveness studies. The 3 costing studies compared directly-observed 3HP to directly-observed 9\u2009months of isoniazid. Of the 7 cost-effectiveness studies, 4 were modelling studies based in high-income countries; one study was modelled on a high tuberculosis incidence population in the Canadian Arctic, using empiric costing data from that setting; and 2 studies were conducted in a low-income, high HIV-coinfection rate population. In five studies, directly-observed 3HP compared to self-administered isoniazid for 9\u2009months in high-income countries, has incremental cost-effectiveness ratios that range from cost-saving to $5418 USD\/QALY gained. While limited, existing evidence suggests 3HP may not be cost-effective in low-income, high HIV-coinfection settings.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Cost-effectiveness should continue to be assessed for programmatic planning and scale-up, and may vary depending on existing systems and local context, including prevalence rates and patient expectations and preferences.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12889-022-14766-6","type":"journal-article","created":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T08:02:48Z","timestamp":1670400168000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic review"],"prefix":"10.1186","volume":"22","author":[{"given":"Wendy A.","family":"Lai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaitlyn","family":"Brethour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivia","family":"D\u2019Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard E.","family":"Chaisson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice A.","family":"Zwerling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,7]]},"reference":[{"key":"14766_CR1","unstructured":"World Health Organization. Global tuberculosis report 2020. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO."},{"issue":"10010","key":"14766_CR2","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1016\/S0140-6736(15)00323-2","volume":"386","author":"MX Rangaka","year":"2015","unstructured":"Rangaka MX, Cavalcante SC, Marais BJ, Thim S, Martinson NA, Swaminathan S, et al. Controlling the seedbeds of tuberculosis: diagnosis and treatment of tuberculosis infection. Lancet. 2015;386(10010):2344\u201353. https:\/\/doi.org\/10.1016\/S0140-6736(15)00323-2.","journal-title":"Lancet."},{"issue":"4","key":"14766_CR3","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1183\/09031936.00214014","volume":"45","author":"K L\u00f6nnroth","year":"2015","unstructured":"L\u00f6nnroth K, Migliori GB, Abubakar I, D\u2019Ambrosio L, de Vries G, Diel R, et al. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J. 2015;45(4):928\u201352. https:\/\/doi.org\/10.1183\/09031936.00214014.","journal-title":"Eur Respir J"},{"issue":"6","key":"14766_CR4","first-page":"935","volume":"95","author":"GW Comstock","year":"1967","unstructured":"Comstock GW, Ferebee SH, Hammes LM. A controlled trial of community-wide isoniazid prophylaxis in Alaska. Am Rev Respir Dis. 1967;95(6):935\u201343.","journal-title":"Am Rev Respir Dis"},{"key":"14766_CR5","first-page":"991","volume":"117","author":"DE Kopanoff","year":"1978","unstructured":"Kopanoff DE, Snider DE Jr, Caras GJ. Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis. 1978;117:991\u20131001.","journal-title":"Am Rev Respir Dis"},{"issue":"1","key":"14766_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6901a1externalicon","volume":"69","author":"TR Sterling","year":"2020","unstructured":"Sterling TR, Njie G, Zenner D, et al. Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep. 2020;69(1):1\u201311. https:\/\/doi.org\/10.15585\/mmwr.rr6901a1externalicon.","journal-title":"MMWR Recomm Rep"},{"key":"14766_CR7","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","volume":"365","author":"TR Sterling","year":"2011","unstructured":"Sterling TR, Vilarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365:2155\u201366.","journal-title":"N Engl J Med"},{"issue":"5","key":"14766_CR8","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1056\/NEJMoa1714283","volume":"379","author":"D Menzies","year":"2018","unstructured":"Menzies D, Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H, et al. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. N Engl J Med. 2018;379(5):440\u201353. https:\/\/doi.org\/10.1056\/NEJMoa1714283.","journal-title":"N Engl J Med"},{"key":"14766_CR9","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s12879-017-2377-x","volume":"17","author":"C Pease","year":"2017","unstructured":"Pease C, Hutton B, Yazdi F, Wolfe D, Hamel C, Quach P, et al. Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regiments for latent tuberculosis infection: a systematic review with network meta-analysis. BMC Infect Dis. 2017;17:265\u201376.","journal-title":"BMC Infect Dis"},{"issue":"8","key":"14766_CR10","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.5588\/ijtld.15.0908","volume":"20","author":"S den Boon","year":"2016","unstructured":"den Boon S, Matteelli A, Getahun H. Rifampicin resistance after treatment for latent tuberculous infection: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2016;20(8):1065\u201371. https:\/\/doi.org\/10.5588\/ijtld.15.0908.","journal-title":"Int J Tuberc Lung Dis"},{"key":"14766_CR11","doi-asserted-by":"publisher","first-page":"689","DOI":"10.7326\/M17-1150","volume":"167","author":"R Belknap","year":"2017","unstructured":"Belknap R, Holland D, Feng PJ, Millet JP, Cayla JA, et al. Self-administered versus directly observed once-weekly isoniazid and rifapentine treatment of latent tuberculosis infection: a randomized trial. Ann Intern Med. 2017;167:689\u201397. https:\/\/doi.org\/10.7326\/M17-1150.","journal-title":"Ann Intern Med"},{"key":"14766_CR12","doi-asserted-by":"publisher","first-page":"723","DOI":"10.15585\/mmwr.mm6725a5","volume":"67","author":"AS Borisov","year":"2018","unstructured":"Borisov AS, Bamrah Morris S, Njie GJ, et al. Update of recommendations for use of once-weekly isoniazid-Rifapentine regimen to treat latent mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep. 2018;67:723\u20136.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3Pt1","key":"14766_CR13","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1164\/ajrccm.162.3.9804117","volume":"162","author":"BD McNab","year":"2000","unstructured":"McNab BD, Marciniuk DD, Alvi RA, Tan L, Hoeppner VH. Twice weekly isoniazid and rifampin treatment of latent tuberculosis infection in Canadian Plains Aborigines. Am J Respir Crit Care Med. 2000;162(3Pt1):989\u201393.","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"14766_CR14","doi-asserted-by":"publisher","first-page":"799","DOI":"10.5588\/ijtld.14.0674","volume":"19","author":"H Bishara","year":"2015","unstructured":"Bishara H, Ore L, Vinitsky O, Bshara H, Armaly N, Weiler-Ravell D. Cost of nurse-managed latent tuberculous infection treatment among hard-to-reach immigrants in Israel. Int J Tuberc Lung Dis. 2015;19(7):799\u2013804.","journal-title":"Int J Tuberc Lung Dis"},{"key":"14766_CR15","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/jama.288.2.165","volume":"288","author":"RE Chaisson","year":"2002","unstructured":"Chaisson RE, Armstrong J, Stafford J, Golub J, Bur S. Safety and tolerability of intermittent rifampin\/pyrazinamide for the treatment of latent tuberculosis infection in prisoners. JAMA. 2002;288:165\u20136.","journal-title":"JAMA"},{"key":"14766_CR16","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/S0002-9343(01)00695-7","volume":"110","author":"RE Chaisson","year":"2001","unstructured":"Chaisson RE, Barnes GL, Hackman J, Watkinson L, Kimbrough L, Metha S, et al. A randomized, controlled trial of interventions to improve adherence to isoniazid therapy to prevent tuberculosis in injection drug users. Am J Med. 2001;110:610\u20135.","journal-title":"Am J Med"},{"key":"14766_CR17","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1001\/archinte.160.5.697","volume":"160","author":"JP Tulsky","year":"2000","unstructured":"Tulsky JP, Pilote L, Hahn JA, Zolopa AJ, Burke M, Chesney M, et al. Adherence to isoniazid prophylaxis in the homeless: a randomized controlled trial. Arch Intern Med. 2000;160:697\u2013702.","journal-title":"Arch Intern Med"},{"key":"14766_CR18","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/j.1471-6712.2011.00935.x","volume":"26","author":"M Sakbakken","year":"2012","unstructured":"Sakbakken M, Bjune GA, Frich JC. Humiliation or care? A qualitative study of patients\u2019 and health professionals\u2019 experiences with tuberculosis treatment in Norway. Scand J Caring Sci. 2012;26:313\u201323.","journal-title":"Scand J Caring Sci"},{"key":"14766_CR19","doi-asserted-by":"publisher","first-page":"e128","DOI":"10.1016\/S1473-3099(16)30531-X","volume":"17","author":"SG De Vries","year":"2017","unstructured":"De Vries SG, et al. Barriers and facilitators to the uptake of tuberculosis diagnostic and treatment services by hard-to-reach population in countries of low and medium tuberculosis incidence: a systematic review of qualitative literature. Lancet Infect Dis. 2017;17:e128\u201343 Published Online March 10, 2017. https:\/\/doi.org\/10.1016\/S1473-3099(16)30531-X.","journal-title":"Lancet Infect Dis"},{"key":"14766_CR20","doi-asserted-by":"publisher","unstructured":"Chavan S, Newlands D, Smith C. A systematic review of economic evaluations of chemoprophylaxis for tuberculosis. J Trop Med. 2011:130976. https:\/\/doi.org\/10.1155\/2011\/130976.","DOI":"10.1155\/2011\/130976"},{"key":"14766_CR21","doi-asserted-by":"publisher","first-page":"f1049","DOI":"10.1136\/bmj.f1049","volume":"346","author":"D Husereau","year":"2013","unstructured":"Husereau D, Drummond M, Petrou S, Greenberg D, Augustovski F, Briggs AH, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. BMJ. 2013;346:f1049.","journal-title":"BMJ"},{"key":"14766_CR22","volume-title":"Methods for the economic evaluation of health care programmes","author":"M Drummond","year":"1997","unstructured":"Drummond M, et al. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford University Press; 1997.","edition":"2"},{"key":"14766_CR23","unstructured":"World Bank. Consumer Price Index https:\/\/data.worldbank.org\/indicator\/FP.CPI.TOTL Accessed 24 Feb 2020."},{"issue":"7","key":"14766_CR24","doi-asserted-by":"publisher","first-page":"e10000097","DOI":"10.1371\/journal.pmed10000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009;6(7):e10000097. https:\/\/doi.org\/10.1371\/journal.pmed10000097.","journal-title":"PLoS Med"},{"issue":"34","key":"14766_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MD.0000000000004126","volume":"95","author":"YW Huang","year":"2016","unstructured":"Huang YW, Yang SF, Yeh YP, Tsao TCY, Tsao SM. Impacts of 12-dose regimen for latent tuberculosis infection: treatment completion rate and cost-effectiveness in Taiwan. Medicine. 2016;95(34):1\u20135.","journal-title":"Medicine"},{"issue":"11","key":"14766_CR26","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1136\/annrheumdis-2018-213097","volume":"77","author":"YM Chen","year":"2018","unstructured":"Chen YM, Liao TL, Chen HH, Chen DY. Three months of once-weekly isoniazid plus rifapentine (3HP) in treating latent tuberculosis infection is feasible in patients with rheumatoid arthritis. Ann Rheum Dis. 2018;77(11):1688\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"1_suppl","key":"14766_CR27","doi-asserted-by":"publisher","first-page":"71S","DOI":"10.1177\/0033354919826557","volume":"134","author":"C Wheeler","year":"2019","unstructured":"Wheeler C, Mohle-Boetani J. Completion rates, adverse effects, and costs of a 3-month and 9-month treatment regimen for latent tuberculosis infection in California inmates, 2011-2014. Public Health Rep. 2019;134(1_suppl):71S\u20139S.","journal-title":"Public Health Rep"},{"issue":"11","key":"14766_CR28","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1164\/rccm.200901-0153OC","volume":"179","author":"DP Holland","year":"2009","unstructured":"Holland DP, Sanders GD, Hamilton CD, Stout JE. Costs and cost-effectiveness o four treatment regimens for latent tuberculosis infection. Am J Respir Crit Care Med. 2009;179(11):1055\u201360.","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"14766_CR29","doi-asserted-by":"publisher","first-page":"e22276","DOI":"10.1371\/journal.pone.0022276","volume":"6","author":"DP Holland","year":"2011","unstructured":"Holland DP, Sanders GD, Hamilton CD, Stout JE. Potential economic viability of two proposed Rifapentine-based regimens for treatment of latent tuberculosis infection. PLoS One. 2011;6(7):e22276. https:\/\/doi.org\/10.1371\/journal.pone.0022276.","journal-title":"PLoS One"},{"issue":"12","key":"14766_CR30","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.5588\/ijtld.13.0423","volume":"17","author":"D Shepardson","year":"2013","unstructured":"Shepardson D, Marks SM, Chesson H, Kerrigan A, Holland DP, Scott N, et al. Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States. Int J Tuberc Dis. 2013;17(12):1531\u20137.","journal-title":"Int J Tuberc Dis"},{"issue":"1","key":"14766_CR31","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1093\/jac\/dky403","volume":"74","author":"TN Doan","year":"2019","unstructured":"Doan TN, Fox GJ, Meehan MT, Scott N, Ragonnet R, Viney K, et al. Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: a decision analysis study. J Antimicrob Chemother. 2019;74(1):218\u201327.","journal-title":"J Antimicrob Chemother"},{"key":"14766_CR32","doi-asserted-by":"publisher","first-page":"e047514","DOI":"10.1136\/bmjopen-2020-047514","volume":"11","author":"C Pease","year":"2021","unstructured":"Pease C, Alvarez G, Mallick R, Patterson M, Finn S, Habis Y, et al. Cost-effectiveness analysis of 3 months of weekly rifapentine and isoniazid compared to isoniazid monotherapy in a Canadian arctic setting. BMJ Open. 2021;11:e047514. https:\/\/doi.org\/10.1136\/bmjopen-2020-047514.","journal-title":"BMJ Open"},{"issue":"7","key":"14766_CR33","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1093\/cid\/ciy230","volume":"67","author":"KT Johnson","year":"2018","unstructured":"Johnson KT, Churchyard GJ, Sohn H, Dowdy DW. Cost-effectiveness of preventive therapy for tuberculosis with isoniazid and rifapentine versus isoniazid alone in high-burden settings. Clin Infect Dis. 2018;67(7):1072\u20138.","journal-title":"Clin Infect Dis"},{"key":"14766_CR34","doi-asserted-by":"publisher","first-page":"e25623","DOI":"10.1002\/jia2.25623","volume":"23","author":"O Ferguson","year":"2020","unstructured":"Ferguson O, Jo Y, Pennington J, Johnson K, Chaisson RE, Churchyard G, et al. Cost-effectiveness of one month of daily isoniazid and rifapentine versus three months of weekly isoniazid and rifapentine for prevention of tuberculosis among people receiving antiretroviral therapy in Uganda. J Int AIDS Soc. 2020;23:e25623. https:\/\/doi.org\/10.1002\/jia2.25623.","journal-title":"J Int AIDS Soc"},{"issue":"6","key":"14766_CR35","doi-asserted-by":"publisher","first-page":"751","DOI":"10.5588\/ijtld.14.0052","volume":"18","author":"D Shepardson","year":"2014","unstructured":"Shepardson D, MacKenzie WR. Update on cost-effectiveness of a 12-dose regimen for latent tuberculous infection at new rifapentine prices. Int J Tuberc Lung Dis. 2014;18(6):751.","journal-title":"Int J Tuberc Lung Dis"},{"key":"14766_CR36","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJMoa1806808","volume":"380","author":"S Swindells","year":"2019","unstructured":"Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, et al. One month of Rifapentine plus isoniazid to prevent HIV-related tuberculosis. N Engl J Med. 2019;380:1001\u201311. https:\/\/doi.org\/10.1056\/NEJMoa1806808.","journal-title":"N Engl J Med"},{"key":"14766_CR37","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1111\/imj.13601","volume":"47","author":"JT Denholm","year":"2017","unstructured":"Denholm JT, McBryde ES, Eisen D, Street A, Matchett E, Chen C, et al. SIRCLE: a randomised controlled cost comparison of self-administered short-course isoniazid and rifapentine for cost-effective latent tuberculosis eradication. Intern Med J. 2017;47:1433\u20136. https:\/\/doi.org\/10.1111\/imj.13601.","journal-title":"Intern Med J"},{"issue":"5","key":"14766_CR38","doi-asserted-by":"publisher","first-page":"e1135","DOI":"10.1093\/cid\/ciaa1835","volume":"73","author":"CM Yuen","year":"2021","unstructured":"Yuen CM, Majidulla A, Jaswal M, Safdar N, Malid AA, Khan AJ, et al. Cost of delivering 12-dose isoniazid and rifapentine versus 6 months of isoniazid for tuberculosis infection in a high-burden setting. Clin Infect Dis. 2021;73(5):e1135\u201341.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"14766_CR39","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.5588\/ijtld.18.0035","volume":"22","author":"MM Macaraig","year":"2018","unstructured":"Macaraig MM, Jalees M, Lam C, Burzynski J. Improved treatment completion with shorter treatment regimens for latent tuberculosis infection. Int J Tuberc Lung Dis. 2018;22(11):1344\u20139.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"14766_CR40","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12879-017-2245-8","volume":"17","author":"AH McClintock","year":"2017","unstructured":"McClintock AH, Eastment M, McKinney CM, et al. Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine. BMC Infect Dis. 2017;17(1):146. https:\/\/doi.org\/10.1186\/s12879-017-2245-8.","journal-title":"BMC Infect Dis"},{"issue":"14","key":"14766_CR41","first-page":"387","volume":"66","author":"EL Holzschuh","year":"2017","unstructured":"Holzschuh EL, Province S, Johnson K, Walls C, Shemwell C, Martin G, et al. Use of video directly observed therapy for treatment of latent tuberculosis infection\u2014Johnson County, Kansas, 2015. MMWR. 2017;66(14):387\u20139.","journal-title":"MMWR"},{"issue":"6","key":"14766_CR42","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1542\/peds.113.6.e514","volume":"113","author":"L Phillips","year":"2004","unstructured":"Phillips L, Carlile J, Smith D. Epidemiology of a tuberculosis outbreak in a rural Missouri high school. Pediatrics. 2004;113(6):514.","journal-title":"Pediatrics"},{"issue":"5","key":"14766_CR43","doi-asserted-by":"publisher","first-page":"633","DOI":"10.5588\/ijtld.11.0504","volume":"16","author":"PC Chan","year":"2012","unstructured":"Chan PC, Yang CH, Chang LY, Wang KF, Lu BY, Lu CY. Et a. latent tuberculosis infection treatment for prison inmates: a randomised controlled trial. Int J Tuberc Lung Dis. 2012;16(5):633\u20138.","journal-title":"Int J Tuberc Lung Dis"},{"key":"14766_CR44","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0376-8716(01)00208-3","volume":"66","author":"SL Batki","year":"2002","unstructured":"Batki SL, Gruber VA, Bradley JM, Bradley M, Delucchi K. A controlled trial of methadone treatment combined with directly observed isoniazid for tuberculosis prevention in injection drug users. Drug Alcohol Depend. 2002;66:283\u201393.","journal-title":"Drug Alcohol Depend"},{"key":"14766_CR45","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1046\/j.1360-0443.1999.947107112.x","volume":"94","author":"PG O\u2019Connor","year":"1999","unstructured":"O\u2019Connor PG, Shi JM, Henry S, Durante AJ, Friedman L, Selwyn PA. Tuberculosis chemoprophylaxis using a liquid isoniazid-methadone admixture for drug users in methadone maintenance. Addiction. 1999;94:1071\u20135.","journal-title":"Addiction"},{"key":"14766_CR46","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1086\/379513","volume":"37","author":"JN Scholten","year":"2003","unstructured":"Scholten JN, Driver CR, Munsiff SS, et al. Effectiveness of isoniazid treatment for latent tuberculosis infection among human immunodeficiency virus (HIV)-infected and HIV-uninfected injection drug users in methadone programs. Clin Infect Dis. 2003;37:1686\u201392.","journal-title":"Clin Infect Dis"},{"key":"14766_CR47","doi-asserted-by":"publisher","first-page":"CD003343","DOI":"10.1002\/14651858.CD003343.pub4","volume":"5","author":"J Karumbi","year":"2015","unstructured":"Karumbi J, Garner P. Directly observed therapy for treating tuberculosis. Cochrane Database Syst Rev. 2015;5:CD003343. https:\/\/doi.org\/10.1002\/14651858.CD003343.pub4.","journal-title":"Cochrane Database Syst Rev"},{"key":"14766_CR48","doi-asserted-by":"publisher","first-page":"118","DOI":"10.2471\/BLT.14.138206","volume":"93","author":"E Marseille","year":"2015","unstructured":"Marseille E, Larson B, Kazi DS, Kahn JG, Rosen S. Thresholds for the cost\u2013effectiveness of interventions: alternative approaches. Bull World Health Organ. 2015;93:118\u201324. https:\/\/doi.org\/10.2471\/BLT.14.138206.","journal-title":"Bull World Health Organ"},{"key":"14766_CR49","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2471\/BLT.15.164418","volume":"94","author":"MY Bertram","year":"2016","unstructured":"Bertram MY, Lauer JA, De Joncheere K, Edejer T, Hutubessy R, Kieny M-P, et al. Cost\u2013effectiveness thresholds: pros and cons. Bull World Health Organ. 2016;94:925\u201330. https:\/\/doi.org\/10.2471\/BLT.15.164418.","journal-title":"Bull World Health Organ"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-022-14766-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-022-14766-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-022-14766-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T08:03:29Z","timestamp":1670400209000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-022-14766-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,7]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["14766"],"URL":"https:\/\/doi.org\/10.1186\/s12889-022-14766-6","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,7]]},"assertion":[{"value":"25 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"WAL, KB, and OD have no competing interests to declare. REC has previously received consulting fees from Sanofi. Sanofi has previously donated study drugs to Johns Hopkins University. AAZ is an associate editor for BMC Infectious Diseases.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2292"}}